PACE-CME

Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

Robust benefits for CV and limb event risk in PAD patients on PCSK inhibition
RestartResume
    3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA
    • Overview

      AHA 2017 PAD patients enrolled in the FOURIER trial who were treated with PCKS9 inhibitor evolocumab showed a higher absolute and relative CV event reduction, and a large reduction in limb events.

    • Educational information

      This 3-minute education provides a summary of just presented scientific data, recorded during the AHA 2017 congress. The objective is to provide a brief commentary and potential implications of these findings.

    • Disclosures

      - Our reporting is based on the information provided at the AHA 2017 congress -

      The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

    Facebook Comments

    Register

    We’re glad to see you’re enjoying PACE-CME…
    but how about a more personalized experience?

    Register for free